Interestingly, elevated tau levels, including specific phosphorylated epitopes (P-tau181, P-tau231, and P-tau199) and N-terminal tau fragments truncated at 224, are not seen in many neurodegenerative diseases including primary tauopathies, such as frontotemporal dementia (FTD) or progressive supranuclear palsy (PSP) [24, 27–29]. Here, MAPT is linked to progressive supranuclear palsy.